Cytomegalovirus Infection Monitoring Based on Interferon Gamma Release Assay in Kidney Transplantation

Gracia-Guindo, M.d.C. De; Ruiz-Fuentes, María del Carmen; Galindo-Sacristán, P.; Osorio-Moratalla, José Manuel; Ruiz-Fuentes, Nuria; Granger, Javier Rodríguez; Osuna-Ortega, Antonio

doi:10.1016/j.transproceed.2017.09.052

Cited by 16 publications

(13 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the majority of SOT patients, IGRAs can be performed at any time before and not earlier than 30 days after the transplant. In SOT experiences, IGRAs were performed before transplant, after transplant before CMV infection, or after CMV infection (Table ) . Positive IGRAs, both before and after SOT, were variably predictive of a lower risk of CMV infection/disease, longer CMV‐free period, spontaneous viral clearance, lower rate of CMV infection recurrence, and lower level of CMV DNAemia.…”

Section: Resultsmentioning

confidence: 99%

Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies

Girmenia

Lazzarotto

Bonifazi

et al. 2019

Clinical Transplantation

View full text Add to dashboard Cite

Cytomegalovirus (CMV) remains a major cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation (allo-HSCT) and solid organ transplantation (SOT) recipients. In view of the uncertainties on the assessment and prevention of CMV infection in both transplant procedures, three Italian scientific societies for HSCT and SOT and for Clinical Microbiology appointed a panel of experts to compose a framework of recommendations. Recommendations were derived from a comprehensive analysis of the scientific literature and from a multidisciplinary consensus conference process. The lack of adequate clinical trials focused on certain

show abstract

Section: Resultsmentioning

confidence: 99%

Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies

Girmenia

Lazzarotto

Bonifazi

et al. 2019

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…Felipe et al [10] in their research stressed that the incidence of CMV events is high in kidney transplant recipients and it may be associated with higher incidence of acute rejection and changes in mmunosuppression. De Gracia-Guindo et al [11] in their study found that interferon gamma (IFN-γ) response measured by the Quantiferon-CMV (QF-CMV) is a protective factor against CMV infection in post-transplantation kidney recipients. Similarly, Tedesco-Silva et al [12] in their study suggested that receiving everolimus and reducing TAC doses decreased the incidence of Cytomegalovirus infection in kidney transplants.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of early and late-term infections after renal transplantation: Clinical experiences of Sanko University Medical Faculty Transplantation Center

Kazımoğlu

Harman

Mercimek

et al. 2019

Turkish Journal of Urology

View full text Add to dashboard Cite

The most common complication after renal transplantation are infections. The majority of the infections are seen within the first year especially between 1-6 months. Post-transplant infections are often related to urinary system. E.coli is the most frequently isolated agent and it may be responsible for urosepsis in renal transplant patients. Infection more often seen in renal transplantations from cadavers.

show abstract

“…In recent years, numerous studies have assessed the role of T-cell immunological monitoring to determine the risk of CMV disease after solid organ and allo-HSCT. [31][32][33][34][35][36][37] In both settings, after documenting CMV-specific T-cell responses, observation in the wait of a spontaneous viral clearance, with no or only short term administration of any antiviral treatment, could be considered. However, if poor or absent CMVspecific T-cell responses are observed, more intensive viral monitoring and more aggressive antiviral prophylaxis or therapy strategies may be considered.…”

Section: Infection and Cmv-specific T Cell Responsementioning

confidence: 99%

An update on the treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation

Madon

Busca

Costa

et al. 2019

Expert Review of Hematology

View full text Add to dashboard Cite

Human Cytomegalovirus (CMV) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Frequency of CMV infection and disease after allo-HSCT depend on several factors including virus-host interactions, recipient-donor CMV serology, donor type (HLA-identical vs. haplo-identical donors)and intensity of conditioning regimens. Moreover, monitoring strategies, cutoff values of viremia to guide prophylactic, preemptive, and treatment interventions remain to be determined. Broader knowledge in CMV biology and its relationship with the host immune-system is greatly contributing to develop novel therapeutic approaches including the application of novel antiviral drugs, with improved toxicity profiles currently under investigation in randomized phase II and III trials, and cell therapy approaches. Significant evidence of the clinical efficacy of adoptive T-cell therapy (ATCT) from CMV-seropositive donors is also emerging. Alternative methods allow ATCT also in allo-HSCT recipients of seronegative donors and cord blood grafts. Vaccine-immunotherapy has the difficult task to reduce the incidence of CMV reactivation/infection in immunocompromised allo-HSCT patients and reach CMV immune control. In this manuscript, we update a previous review by also including recent developments in the virology lab and their possible association with treatment strategies at bedside.

show abstract

Cytomegalovirus Infection Monitoring Based on Interferon Gamma Release Assay in Kidney Transplantation

Cited by 16 publications

References 10 publications

Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies

Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies

Evaluation of early and late-term infections after renal transplantation: Clinical experiences of Sanko University Medical Faculty Transplantation Center

An update on the treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation

Contact Info

Product

Resources

About